Samba Signs 1.1 Trillion Won Pharmaceutical Production Contract with European Pharmaceutical Company.. Acquisition of Local Production Plant in the U.S.

|Smart Today=Reporter Kim Se-hyung| Samsung Biologics announced on the 22nd that it signed a contract for consignment production of pharmaceuticals worth 1.1 trillion won with a European pharmaceutical company on the 19th. The long-term contract is set for five years until December 31, 2030. This corresponds to 24.42% of last year's sales.

Meanwhile, Samsung Biologics also announced that it will acquire 100% of the shares of Human Genome Sciences Inc., a U.S. pharmaceutical manufacturer, for 413.6 billion won through its local subsidiary in the U.S.

This acquisition of local production facilities in the U.S. is to respond to long-term local demand. It will be purchased from GSK. The amount is approximately 280 million dollars based on the dollar.